Assessment of Placebo Response in Objective and Subjective Outcome Measures in Rheumatoid Arthritis Clinical Trials

Authors:

Abstract
Variability in the magnitude of clinical responses in the placebo arms of randomized clinical trials (RCTs) can result in effective drugs failing to reach the clinic. Placebo arms in RCTs are designed to control for the nonspecific effects of enrollment, including standard of care, regression to the mean, natural history of the disease, and placebo effects.1 Placebo arms should be kept as small as possible to avoid withholding potentially effective treatment from patients.2 It is important to distinguish between the placebo effect (a distinct physiological response to the therapeutic context and treatment delivery)3 and the placebo response in a clinical trial (improvement of patients in a placebo arm for any reason). Placebo effects are particularly strong in subjective outcomes (eg, pain),4 functional conditions (eg, irritable bowel syndrome),5 and fatigue,6 leading to the idea that placebo responses in clinical trials could be reduced by using objective biomarkers as primary outcomes rather than patient-reported outcomes. This approach, however, is indirect, since little is known about how objective and subjective outcomes vary in the placebo arms of RCTs7 and the approach ignores the role of other factors in the generation of the placebo response observed in an RCT. To directly compare placebo responses in objective biomarkers and subjective patient-reported outcomes, rheumatoid arthritis RCTs are ideal, as they usually collect data for assessment of patient-reported pain levels as well as changes in objective biomarkers (C-reactive protein [CRP] levels or erythrocyte sedimentation rate [ESR]),8 enabling insights into the magnitude of placebo effects within the placebo response in a homogeneous patient population. In the present study, we analyzed outcomes in the placebo arms of 5 RCTs of rheumatoid arthritis, comparing CRP level, ESR, and subjective pain levels. We hypothesized that, if the placebo effect is a leading contributor to the placebo response in these trials, the placebo response will be higher in pain levels, which are considered to be subjective compared with objective biomarkers. If, however, the placebo effect is superimposed by natural history disease fluctuation, regression to the mean phenomena, and other contributors to the placebo response in clinical trials, one would expect to note only minor differences between objective and subjective outcomes.

This publication has 24 references indexed in Scilit: